Kairos Pharma, Ltd. (KAPA) Stock Forecast
KAPA analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.33 / 5 from 3 analysts
- Price target
- $7.00 average of analyst targets
- Upside to target
- +1,064.7% from the latest close
- Next earnings
- November 13, 2026 EPS estimate $-0.63
- 52-week range
- $0.60 – $8.19
KAPA analyst ratings
3 analystsNumber of analysts at each rating.
KAPA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
KAPA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.09 | −$0.09 | −$0.09 | −$0.07 | −28.6% | 1 |
| Current fiscal year (2026) | −$0.37 | −$0.37 | −$0.37 | −$0.30 | −23.3% | 1 |
| Next fiscal year (2027) | −$0.67 | −$0.67 | −$0.67 | −$0.37 | −81.1% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
KAPA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 2 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 2 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 2 |
KAPA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
KAPA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.09 | −$0.09 | −$0.09 | −$0.09 | −$0.09 | 0.0% | 0 up · 0 down |
| Current fiscal year (2026) | −$0.38 | −$0.37 | −$0.37 | −$0.37 | −$0.37 | −2.6% | 1 up · 0 down |
| Next fiscal year (2027) | −$0.55 | −$0.67 | −$0.67 | −$0.67 | −$0.67 | +22.9% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
KAPA earnings surprises
Reported EPS vs the consensus estimate for the last 9 quarters; KAPA beat in 2 of 9.
What analysts expect from KAPA
3 analysts cover Kairos Pharma; their consensus rating is buy (4.33 on a 1–5 scale, where 5 is a strong buy). The average price target is $7.00, 1,064.7% above the latest close of $0.60. Analysts expect earnings of −$0.37 per share for 2026, −23.3% from a year earlier. For 2027 the average estimate is −$0.67 per share. Kairos Pharma beat the EPS estimate in 2 of the last 9 quarters.
Related: KAPA income statement, KAPA key metrics, KAPA chart. See the KAPA stock overview for the latest quote and news.
KAPA forecast FAQ
What is Kairos Pharma's price target?
The average analyst price target for Kairos Pharma is $7.00, 1,064.7% above the latest close of $0.60.
Is Kairos Pharma a buy, hold or sell?
Of 3 analysts covering Kairos Pharma, 1 rate it a strong buy, 2 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Kairos Pharma's EPS forecast?
Analysts forecast −$0.37 per share for 2026 (range −$0.37 to −$0.37); for 2027 the estimate is −$0.67.
When does Kairos Pharma report earnings?
Kairos Pharma is expected to report results for the quarter ending September 30, 2026 on November 13, 2026; the EPS estimate is $-0.63.
Does Kairos Pharma usually beat earnings estimates?
Kairos Pharma reported EPS at or above the analyst estimate in 2 of the last 9 quarters.